REMINDER: Our user survey closes on Friday, please submit your responses here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Surely we are worth more than 1billion
How much then ?
Think 1bn approx £2.81 if my math correct.
Recent Share Trades for Avacta Group (AVCT)
Date Time Trade Prc Volume Buy/Sell Value
02-May-24 17:07:29 46.50 5,000 Unknown* 2,325 O
02-May-24 16:56:19 45.78 100,000 Sell* 45.78k O
02-May-24 16:43:52 45.644 -85,000 Unknown* -38.80k O
02-May-24 16:52:08 46.188 325,000 Sell* 150.11k O
02-May-24 16:43:52 45.644 85,000 Sell* 38.80k O
02-May-24 16:38:29 46.25 100,000 Sell* 46.25k O
Potentially a 1.75bn deal for preclinical. Would expect more here tbh based on the data. See what happens, if BP were negotiating with Avacta on a take-over deal, the placing would make sense as that would protect negotiating strength money in the bank. Up your offer or we have the capability to go solo phase 2 and do license deals. Nothing off the table suggests this scenario does have some merit however that’s just pure speculation on my part. Very interesting though 🤔🤔💯
1 billion equates to a fiver per share?
You seriously need a new calculator.
Gje306
Look at the f*cking slide. Chris specifically made the point that there was no higher dox in the biopsies from high FAP expressing tumours than the mid FAP ones. And this was something they were surprised and encouraged by.
That is why it is pointless discussing things on here because half the posters only hear what they want to hear.
Some people post a lot but also produce a lot of Scheiße.
1billion take over suits me. What s. That a fiver per share?
1 billion, pah!! That's no where near £200 ex chi-nah
I anticipate CC will be much more open to deals or a takeover than AS was. AS had been at the helm for 18 years and I imagine Avacta was his baby.
Well they missed out to EL on the Point Deal...and they will know all about Avacta, our new CEO, our trials/data...just a matter of time...
'POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer. http://www.pointbiopharma.com. External link for POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company. Industry Biotechnology.
https://www.linkedin.com › company
POINT Biopharma, a wholly owned subsidiary of Eli Lilly ...
Bella where is the 500k trade ?
Bach Bioscience
1.Tumor Micro-enviroment Activated Drug (TMACs).
A platform technology—currently focused on using FAP as the tumor specific enzyme for activation.
Example: AVA6000 releases Doxorubicin. Currently licensed to Avacta Life sciences and is in phase 1 human clinical trials.
2.Tumor Microenvironment Localized drugs. (TMELDs).
Also platform technology currently focused on using FAP, but exploits binding to FAP rather than activation.
Example: PNT6555. A radiotheranostic licensed to Point Biopharma and currently in phase 1 human clinical trials.
3.Can-SEEK.
FAP activated PSMA or folate receptor targeted Radio theranostics. Ongoing collaboration with Point Biopharma. Lead candidates have been designed and synthesized and currently being characterized.
Disappointed the bot didn’t post it first. Praise given where it’s due, as always
Here's the full published article/text from Jan 2024
https://jnm.snmjournals.org/content/65/1/100.long
PNT6555 looking good.
PL is Hurstbot .
PL have you been abducted by Aliens ? Praising RAH
Have been shopping…. $1bn for preclinical. Thanks to Rah for sharing on twatter.
https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-buy-radiology-specialist-mariana-oncology-1-billion-2024-05-02/
Lolz a plenty if one of the options that’s back on the table is agreeing to a takeover. I’d suggest a bit more than $1bn given platform technologies and being in the clinic. You could imagine Alan digging his heels in and you could imagine Chris thinking a quick payday could work out nicely.
'PERTINENT FINDINGS: Boronic acid–based DOTA-FAPIs are potent, selective inhibitors of soluble and membrane-associated forms of FAP. In a FAP-positive tumor model, the 68Ga-chelates of PNT6555 and PNT6952 exhibited appropriate properties for PET imaging, and the 177Lu-chelates of PNT6555, PNT6952, and PNT6522 produced strong anticancer effects, with PNT6555 exhibiting the most potent antitumor activity when chelated with 177Lu and similar activity when chelated with 225Ac or 161Tb, suggesting versatility in therapeutic applications.
IMPLICATIONS FOR PATIENT CARE: PNT6555- and 3099-based analogs provide feasible alternatives to quinoline-based DOTA-FAPIs, and the preclinical results support their translation to the clinic for theranostic applications in oncology.'
Apologies if already posted...
https://www.pharmaceutical-technology.com/data-insights/177lu-pnt6555-point-biopharma-global-solid-tumor-likelihood-of-approval/?cf-view
Touk, are you back making stuff up again?
Probably more the fact the Dox sensitive tumours is in the high FAP category and they would guarantee a response from the platform cleaving and dumping the warhead. You wouldn’t want to take any chances, with using mid or low fap tumours just incase you get inferior results. If they design other warheads to target mid fap tumours that are sensitive to that warhead happy days.
Ice
Why high FAP. Chris explain a slide demonstrating that level of FAP wasn’t a determinant in amount of fox in the tumour biopsies
I don't believe they can run the various dose levels in parallel, only patients within a dose cohort. Again, ambiguous comms lead to these kinds of debates.